Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cumberland Emerging Technologies Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being processed in 1 distinct art unit, indicating a concentrated area of technical review. The prosecution is assigned to 1 distinct examiner, EVAN MICHAEL LEWOCZKO. This concentration of the pending workload into a single art unit and examiner suggests a very specific regulatory path for the company's pharmaceutical innovations at this time.
EVAN MICHAEL LEWOCZKO is the busiest examiner for this company, currently handling 1 pending office action. This examiner is responsible for the only active office action in the company's portfolio. Consequently, the immediate prosecution goals are entirely dependent on the feedback from this single examiner. There is no current opportunity to compare examiner behavior across different applications within this portfolio, as only 1 pending office action exists.
With 1 pending office action and 1 distinct examiner, the prosecution landscape is currently very focused. There are no other art units or examiners involved in pending matters for Cumberland Emerging Technologies Inc. Practitioners should focus on the specific standards of the 1 distinct art unit where this action is pending. This concentrated activity allows for a dedicated approach to the single application currently under review by EVAN MICHAEL LEWOCZKO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728193 | DETECTION AND LOCALIZATION OF INTERNAL BLEEDING | LEWOCZKO, EVAN MICHAEL | 1612 | §103 | Non-Final OA | — | Pending | Jul 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCumberland Emerging Technologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Evan Michael Lewoczko has the most, with 1 of Cumberland Emerging Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
